Redox Limited

The Business

Redox distributes industrial and specialty chemicals across roughly 170 industries, sourcing from more than 1,200 suppliers and selling to over 8,700 customers. Australia contributes the bulk of revenue and remains the group's mature, cash-generative core. A smaller but fast-growing North American operation, now around $100 million of revenue, is the group's stated growth avenue. The business model is capital-light: distribution, storage and a proprietary logistics platform rather than manufacturing, which explains both the modest fixed asset base and the working capital intensity that comes with holding inventory across thousands of stock-keeping units.

Recent Performance

Revenue grew 6.9% in FY26 to $1,330 million, building on 9.4% growth the prior year, a deceleration consistent with a maturing base rather than a demand shock. Gross margin expanded to a five-year high of 22.4%, and EBITDA margin recovered to 10.1% from a FY25 trough. The share price has moved up alongside this operating improvement, and at current levels the market appears to be pricing in a more favourable trajectory for margins and growth than the organic business has demonstrated to date.

Outlook

We expect revenue growth to decelerate further over the next few years as the Australian base matures and North American growth normalises off its current 34% pace. EBITDA margin should see modest further gains as the US business gains scale, before wage inflation and competitive pressure cap additional expansion. Gross margin is more likely to fade from its current peak than hold there, a headwind our forecasts already account for rather than a risk we are flagging as a surprise.

Key Risks

The most significant risk is that the market is pricing in acquisitions Redox has not yet made. The company holds substantial deployable capital and has stated comfort with higher leverage, yet executed zero acquisitions in FY26. That discipline protects against overpaying, but it also means the current price already assumes a level of deal-making the company has not delivered.

Gross margin sits at a five-year peak, and a reversion toward the historical average is a live possibility as freight costs normalise and competitive intensity in Asia-Pacific chemical distribution increases, particularly if a global specialty distributor such as IMCD or Brenntag expands further into the region. We treat this as a moderate-probability risk rather than a central case, but the margin has limited room to expand further from here.

Working capital tied up at around 30% of revenue, versus roughly 20% for global distribution peers, structurally caps free cash flow conversion at 55-65% of EBITDA. This is not a temporary inefficiency; it reflects a buy-hold-resell model spanning more than 5,500 products across multiple regulatory regimes, and it means Redox's cash generation will consistently lag its reported earnings growth regardless of how well the underlying business performs.

What to Watch

The thesis-defining event is the H1 FY27 result in February 2027, which will confirm whether gross margin holds near its recent highs and whether the North American business is tracking toward its scale targets.

• Feb 2027 H1 FY27 results — confirms North American trajectory and gross margin sustainability.
• 12-18 months M&A announcement — a bolt-on deployed at 8-10x EBITDA would validate the market's current pricing of acquisition optionality.

Company Description

Redox is an Australian chemical and ingredients distributor, sourcing from more than 1,200 global suppliers and distributing across roughly 170 end industries, from agriculture and construction to food and pharmaceuticals. The business operates through three geographic segments: Australia, its largest and most mature market; New Zealand, a smaller, steady contributor; and North America, the group's newest growth market at around $100 million of revenue. A proprietary logistics and compliance platform, built over two decades, manages more than 5,500 stock-keeping units across different regulatory regimes. The company does not manufacture; it buys, stores and resells, earning its margin on distribution, storage and technical service rather than on chemical production itself.

Where the Growth Is

North America is the single most important growth lever. It contributes around 7.5% of group revenue today but is growing 34% year-on-year, well ahead of the mature Australian base. We model this decelerating toward mid-single digits over the coming decade as the base scales, but even on that conservative path, North America has a credible route to $250 million or more of revenue within five years. This scaling represents the clearest source of incremental value creation within the current strategy, though the outcome is not yet assured, and a stalled expansion would meaningfully dent the growth case the market is currently crediting the business with.

Competitive Position

Redox's advantage rests on breadth rather than depth. Where specialty-focused competitors such as IMCD concentrate on higher-margin niche chemicals, Redox spans both commodity and specialty products across 170 industries, a structure that dilutes average margin but diversifies demand risk. Its proprietary platform, developed over more than 20 years, manages regulatory compliance and inventory across thousands of products, a capability a new entrant could not replicate quickly. This translates into a defensible, if not unassailable, regional position: we see the advantage holding for roughly five to seven years before global consolidators erode it further. The clearest threat is a large specialty distributor such as IMCD or Brenntag expanding into Asia-Pacific through acquisition, which would compress pricing power in Redox's higher-margin categories. There is no evidence yet of Redox losing share domestically, and the business has weathered sixty years of industry cycles without financial stress.

Management & Capital Discipline

The founding family retains roughly 60% ownership, which aligns management incentives closely with shareholders and has underpinned a conservative, cycle-tested balance sheet. Management has delivered on its stated FY26 targets: the North American milestone, the free cash flow conversion target, and the gross margin recovery all came through as guided. The less flattering observation is capital allocation: Redox sits on roughly $304 million of deployable capital, has stated comfort with leverage of 2.0 to 2.5 times earnings, and yet executed zero acquisitions in FY26. That conservatism protects against overpaying, but it also means idle capital earning bank deposit rates rather than the 14.6% the core business generates, a compounding opportunity cost the longer it persists.

Financial Position

Redox carries no net debt and holds around $123 million of cash against roughly $304 million of total deployable capacity once undrawn facilities are included. Return on invested capital of 14.6% comfortably clears the 10.25% cost of capital, and the balance sheet has no financial stress even in weaker demand periods. The company could absorb a genuine industrial downturn without covenant risk or dividend cuts. The dividend itself is fully franked and covered by free cash flow, though conversion is structurally lower than global peers because of the working capital tied up in inventory across 5,500 products.